Know Cancer

or
forgot password

Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients


Phase 2
18 Years
70 Years
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients


Inclusion Criteria:



A woman will be eligible for inclusion in this study if she meets all of the following
criteria:

- Has HER2+ (IHC staining of 3+ [uniform, intense membrane staining of >30% of invasive
tumor cells], or a FISH result of .6 HER2 gene copies per nucleus or a FISH ratio
[HER2 gene signals to chromosome 17 signals] of >2.2; patients with equivocal FISH
ratio results 1.8-2.2 are also eligible if 3+ IHC) (Appendix IX); Stage I, IIA, IIB,
or IIIA T1-3N1-3M0 disease. At the discretion of the Treating Physician, patients
with 4+ nodes with other factors such as patient choice, older age, preexisting
cardiac disease with normal MUGA or ECHO may be enrolled into a separate subgroup.

- Has operable, histologically confirmed, invasive carcinoma of the breast.

- Has known ER and PR status

- Has adequate tumor specimen available for FISH analysis of TOP2A status (See Appendix
VII)

- Has had no prior chemotherapy unless it was given >5 years ago for breast cancer or
other cancer

- Has an ECOG Performance Status (PS) 0-1

- Age >18 to <70 years old.

- Has laboratory values of: See protocol for specific details

- Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline
phosphatase (ALP) within the ranges shown below. In determining eligibility the more
abnormal of the 2 values (AST or ALT) should be used. See protocol for specific
details

- Has complete surgical resection of the primary breast tumor: either lumpectomy or
mastectomy with sentinel lymph node or axillary dissection.

- It has been <84 days since the date of definitive surgery, and there is adequate
wound healing as determined by the Treating Physician

- Has no evidence of metastatic disease by physical examination and x-ray; appropriate
scans as needed by each individual patient (eg, bone scan; abdominal, chest CT; PET
or PET/CT; ultrasound; or MRI should indicate no evidence of metastatic disease.

- Has normal cardiac function as evidenced by a LVEF >50%, but must be within normal
limits (WNL) by institutional standard, as determined by multiple gated acquisition
(MUGA) scan. An echocardiogram (ECHO). The same modality must be used throughout the
study to evaluate LVEF. Ejection fraction (EF) as determined by ECHO must be WNL by
institutional standard.

- Has a negative serum pregnancy test within 7 calendar days prior to registration
(female patients of childbearing potential [not surgically sterilized and between
menarche and 1 year postmenopause]).

- If fertile, patient has agreed to use an acceptable method of birth control (barrier
contraceptive) to avoid pregnancy for the duration of the study and for a period of 3
months thereafter

- Has signed a Patient Informed Consent Form

- Has signed a Patient Authorization Form

Exclusion Criteria:

A woman will be excluded from this study if she meets any of the following criteria:

- Has any evidence of disease following complete surgical resection of the primary
tumor and metastatic workup

- Has Stage IIIB breast cancer (T4 disease; ie, patients with fixed tumors, peau
d'orange skin changes, skin ulcerations, or inflammatory changes).

- Has Stage IV breast cancer (M1 disease on TNM staging system)

- Had prior chemotherapy for breast cancer or other cancer within the last 5 years (no
neoadjuvant chemotherapy in this study is permitted)

- Has a history of severe hypersensitivity reaction to drugs formulated with
polysorbate 80

- Has had a myocardial infarction (MI) within 6 months of trial enrollment, or has New
York Heart Association (NYHA) Class II or greater heart failure (see Appendix III),
uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically
significant pericardial disease, or electrocardiographic evidence of acute ischemic
changes

- Has abnormal baseline MUGA (or ECHO) (<50%, or less than institutional LLN)

- Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy.
Adjuvant hormonal therapy, if needed, may be given during radiation therapy and
during treatment with trastuzumab after completion of chemotherapy.

- Is receiving concurrent investigational therapy or has received such therapy within
the past 30 calendar days

- Has peripheral neuropathy >Grade 1

- Has a serious uncontrolled intercurrent medical or psychiatric illness, including
serious viral (including clinically defined AIDS), bacterial or fungal infection; or
history of uncontrolled seizures, or diabetes, or CNS disorders deemed by the
Treating Physician to be clinically significant, precluding informed consent

- Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is
known to be HIV positive

- Has a history of other malignancy within the last 5 years (except cured basal cell
carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the
diagnosis or assessment of any of the study drugs

- Is an obese patient to whom the Treating Physician would not be comfortable
administering full doses of study drugs as calculated by the BSA. Obese patients will
be treated based on actual body weight. Obese patients treated with full doses based
on actual BSA are eligible

- Is a pregnant or breastfeeding woman

- Is deemed unable to comply with requirements of study

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the DFS at 2 years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC patients treated with TC+H.

Outcome Time Frame:

To determine the DFS at 2 years

Safety Issue:

No

Principal Investigator

Stephen E Jones, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

US Oncology Research

Authority:

United States: Institutional Review Board

Study ID:

06-038

NCT ID:

NCT00493649

Start Date:

June 2007

Completion Date:

February 2011

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location

Texas Oncology, P.A.Dallas, Texas  75246
Virginia Oncology AssociatesNewport News, Virginia  23606
Comprehensive Cancer Centers of NevadaLas Vegas, Nevada  89109
Ocala Oncology CenterOcala, Florida  34474
Cancer Centers of the CarolinasGreenville, South Carolina  29605
Missouri Cancer AssociatesColumbia, Missouri  65201
New Mexico Cancer Care AssociatesSanta Fe, New Mexico  87505-7670
Tyler Cancer CenterTyler, Texas  75702
Hope CenterTerre Haute, Indiana  47809
Willamette Valley Cancer CenterEugene, Oregon  97401-8122
San Antonio Tumor and Blood ClinicSan Antonio, Texas  78217
New York Oncology Hematology, P.C.Albany, New York  12208
Cancer Centers of Florida, P.A.Orlando, Florida  
Northwest Cancer Specialists-VancouverVancouver, Washington  98684
Medical Oncology AssociatesKingston, Pennsylvania  18704
Florida Cancer InstituteNew Port Richey, Florida  34652
Central Indiana Cancer CentersIndianapolis, Indiana  46227
Minnesota Oncology Hematology, P.A.Minneapolis, Minnesota  55407
Texas Cancer Center at Medical CityDallas, Texas  75230
Allison Cancer CenterMidland, Texas  79701
Texoma Cancer CenterWichita Falls, Texas  76310
Highline Medical OncologyBurien, Washington  98166
Hematology Oncology AssociatesPhoenix, Arizona  85012
Arch Medical Services, INC.St. Louis, Missouri  63142
Greater Dayton Cancer CenterKettering, Ohio  45409
Birmingham Hematology and OncologyBirmingham, Alabama  35235
Texas Cancer CenterAbilene, Texas  79606
Texas Oncology Cancer CenterAustin, Texas  78731
Mamie McFaddin Ward Cancer CenterBeaumont, Texas  77702
Lake Vista Cancer CenterLewisville, Texas  75067
Longview Cancer CenterLongview, Texas  75601
Texas Cancer Center of MesquiteMesquite, Texas  75150
Onc and Hem Associates of SW VA, Inc.Salem, Virginia  24153
Maryland Oncology Hematology, P.A.Columbia, Maryland  21044
Paris Regional Cancer CenterParis, Texas  75460
Hematology Oncology Associates of ILChicago, Illinois  60611
Cancer Care & Hematology Specialists of ChicagolandNiles, Illinois  60714
Rocky Mountain Cancer Center-RoseDenver, Colorado  80220
Texas Oncology PADallas, Texas  75231
Hematology-Oncology Associates of NNJ, P.A.Morristown, New Jersey  07960
Interlakes Oncology Hematology, PCRochester, New York  14623
El Paso Cancer Treatment CtrEl Paso, Texas  79915
South Texas Cancer Center-McAllenMcAllen, Texas  78503
Texas Cancer Center-ShermanSherman, Texas  75090
Texas Oncology Cancer Center-Sugar LandSugar Land, Texas  77479
Puget Sound Cancer Center-SeattleSeattle, Washington  98133
Cancer Care Northwest-SouthSpokane, Washington  99202
Yakima Valley Mem Hosp/North Star LodgeYakima, Washington  98902
Fairfax Northern VA Hem-Onc PCFairfax, Virginia  22031
Puget Sound Cancer Center-EdmondsEdmonds, Washington  98026
Connecticut Oncology & Hematology, LLPTorrington, Connecticut  06790
Kansas City Cancer Centers-SouthwestOverland Park, Kansas  66210
Ruth Oratz MDNew York, New York  10016
Texas Oncology, P.A.-AmarilloAmarillo, Texas  79106
HOAST-Medical Dr.San Antonio, Texas  78229
Cancer Centers of North CarolinaRaleigh, North Carolina  27607
Northern AZ Hematology & Oncology AssociatesSedona, Arizona  86336
Arizona Oncology Associates DBA HOPETucson, Arizona  85704
Alliance Hematology Oncology P.A.Westminster, Maryland  21157
Texas Cancer Center-Abilene (South)Abilene, Texas  79606
Texas Oncology, P.A.-BedfordBedford, Texas  76022
Methodist Charlton Cancer Ctr.Dallas, Texas  75237
Texas Oncology-OdessaOdessa, Texas  79761
Texas Oncology Cancer Care and ResearchWaco, Texas  76712